Skip to main content
Log in

Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

The paper analyzes the relation among tumor size (T), estrogen receptor (ER) status, and labeling index (LI) and their relative merits in predicting the relapse-free (RFS) and overall survival (OS) in 215 node-negative women with primary breast cancer. All patients were subjected to Halsted or modified radical mastectomy; none received postoperative irradiation or systemic adjuvant therapy. The 5-year RFS was 75.3% and OS 89.0%

When singly tested, LI and ER were able to significantly predict RFS and OS. In contrast, T influenced only RFS but not OS. The multivariate analysis showed that, in the presence of the two other variables, only LI retained its prognostic significance both for time to relapse (p = 0.0044) and survival (p = 0.035). From the present findings, LI appears to be a new important prognostic variable in the selection of high risk patients for whom adjuvant systemic therapy should perhaps be part of their primary treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Stewart JF, Rubens RD: General prognostic factors. In: Bonadonna G (ed): Breast Cancer: Diagnosis and Management, Vol 1. Wiley, New York, 1984, pp. 141–168

    Google Scholar 

  2. Bonadonna G, Valagussa P: Contribution of prognostic factors to adjuvant chemotherapy in breast cancer. Recent Results Cancer Res 96: 34–45, 1984

    PubMed  Google Scholar 

  3. Valagussa P, Brambilla C, Bonadonna G: Advanced breast cancer: Are the traditional stratification parameters still of value when patients are treated with combination chemo-therapy? Eur J Cancer 15: 565–571, 1977

    Google Scholar 

  4. Fisher B, Bauer M, Wickerham DL et al.: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 52: 1551–1557, 1983

    Google Scholar 

  5. Fisher B, Slack NH, Bross IDJ et al.: Cancer of the breast: Size of neoplasm and prognosis. Cancer 24: 1071–1080, 1969

    PubMed  Google Scholar 

  6. Maynard PV, Blamey RW, Elston JW, Haybittle JL, Griffiths K: Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res 38: 4292–4295, 1978

    PubMed  Google Scholar 

  7. Osborne CK, Yochmowitz MG, Knight WA III, McGuire WL: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884–2888, 1980

    PubMed  Google Scholar 

  8. Croton R, Cooke T, Holt S, George WD, Nicolson R, Griffiths K: Oestrogen receptors and survival in early breast cancer. Br Med J 283: 1289–1291, 1981

    Google Scholar 

  9. Aamdal S, Bormer O, Jorgensen O, Host H, Eliassen G, Kaalhus O, Pihl A: Estrogen receptors and long-term prognosis in breast cancer. Cancer 53: 2525–2529, 1984

    PubMed  Google Scholar 

  10. Parl FF, Schmidt BP, Dupont WD, Wagner RK: Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer 54: 2237–2242, 1984

    PubMed  Google Scholar 

  11. Butler JA, Bretsky S, Menendez-Botet C, Kinne DW: Estrogen receptor protein of breast cancer as a predictor of recurrence. Cancer 55: 1178–1181, 1985

    PubMed  Google Scholar 

  12. Bertuzzi A, Vezzoni P, Ronchi E: Prognostic importance of progesterone receptors alone or in combination with estrogen receptors in node negative breast carcinoma (Abstr). Proc Am Soc Clin Oncol 22: 447, 1981

    Google Scholar 

  13. Clark GM, McGuire WL, Hubay CA, Pearson OH, Marshall JS: Progesterone receptor as a prognostic factor in stage II breast cancer. N Engl J Med 309: 1343–1347, 1983

    PubMed  Google Scholar 

  14. Alanko A, Heinonen E, Scheinin TM, Tolppanen EM, Vihko R: Oestrogen and progesterone receptors and disease-free interval in primary breast cancer. Br J Cancer 50: 667–672, 1984

    PubMed  Google Scholar 

  15. Gentili C, Sanfilippo O, Silvestrini R: Cell proliferation and its relationship to clinical features and relapse in breast cancers. Cancer 48: 974–979, 1981

    PubMed  Google Scholar 

  16. Meyer JS, Friedman E, McCrate MM, Bauer WC: Prediction of early course of breast carcinoma by thymidine labeling. Cancer 51: 1879–1886, 1983

    PubMed  Google Scholar 

  17. Tubiana M, Pejovic MH, Chavaudra N, Contesso G, Malaise EP: The long-term prognostic significance of the thymidine labeling index in breast cancer. Int J Cancer 33: 441–445, 1984

    PubMed  Google Scholar 

  18. EORTC Breast Cancer Cooperative Group: Standards for the assessment of estrogen receptors in human breast cancer. Eur J Cancer 9: 379–381, 1973

    Google Scholar 

  19. Scatchard G: The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51: 600–672, 1949

    Google Scholar 

  20. Fleiss JL: Statistical Methods for Rates and Proportion. Wiley, New York, 1973

    Google Scholar 

  21. Peto R, Pike MC, Armitage P et al.: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Analysis and examples. Br J Cancer 35: 1–39, 1977

    PubMed  Google Scholar 

  22. Cox DR: Regression models and life table (with discussion). J Roy Stat Soc (B) 34: 187–220, 1972

    Google Scholar 

  23. Bertuzzi A, Daidone MG, Di Fronzo G, Silvestrini R: Relationship among estrogen receptors, proliferative activity and menopausal status in breast cancer. Breast Cancer Res Treat 1: 253–262, 1981

    PubMed  Google Scholar 

  24. Valagussa P, Bonadonna G, Veronesi U: Pattern of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer 41: 1170–1178, 1978

    PubMed  Google Scholar 

  25. Fisher B, Slack N, Katrych DL, Wolmark N: Ten-year follow-up of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 140: 528–534, 1975

    PubMed  Google Scholar 

  26. Valagussa P, Bignami P, Buzzoni R et al.: Are estrogen receptors alone a reliable prognostic factor in node negative breast cancer? In: Jones SE, Salmon SE (eds): Adjuvant Therapy of Cancer IV. Grune and Stratton, New York, 1984, pp 407–415

    Google Scholar 

  27. Silvestrini R, Daidone MG, Gasparini G: Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer 56: 1982–1987, 1985

    PubMed  Google Scholar 

  28. Williams MR, Nicholson RI, Elston CW, Todd J, Griffiths K, Blamey RW: Oestrogen receptors in primary breast cancer. Br J Cancer 51: 907–909, 1985

    PubMed  Google Scholar 

  29. Adami HO, Graffman S, Lindgren A, Sallstrom J: Prognostic implication of estrogen receptor content in breast cancer. Breast Cancer Res Treat 5: 293–300, 1985

    PubMed  Google Scholar 

  30. Black MM, Hankey BF, Barclay THC: Intrastage prognostic heterogeneity: implications for adjuvant chemotherapy of breast cancer. J Natl Cancer Inst 68: 445–447, 1982

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Presented in part at the Annual Meeting of the American Socicty of Clinical Oncology, May, 1985, Houston, Texas, USA.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Silvestrini, R., Daidone, M.G., Di Fronzo, G. et al. Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer. Breast Cancer Res Tr 7, 161–169 (1986). https://doi.org/10.1007/BF01806246

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01806246

Keywords

Navigation